POLARITYTE, INC.
DelistedCIK 1076682fmd_1DPY13FE2F76BZJBFH2FCJ2J87Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Nov 01, 2008 to Mar 31, 2023, 56 periods
| Line item | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 34 | 7 | 2 | – | – | 2 | 6 | 10 | 9 | 1 |
| Cost of revenue | 29 | 3 | 0 | – | – | 1 | 2 | 4 | 4 | 1 |
| Net interest income | – | – | – | – | – | – | 0 | (0) | (0) | (0) |
| Gross profit | 6 | 3 | 1 | – | – | 1 | 3 | 6 | 5 | 0 |
| Research and development | 2 | 0 | 0 | 7 | – | 18 | 16 | 12 | 14 | 11 |
| Selling, general and administrative | 16 | 6 | 6 | – | – | 58 | 80 | 36 | 23 | – |
| Total operating expenses | 19 | 7 | 4 | 131 | – | – | – | – | – | – |
| Operating income | (13) | (4) | (4) | (131) | – | (75) | (93) | (46) | (34) | (22) |
| Interest expense | 0 | 0 | (0) | – | – | – | – | – | – | – |
| Income before taxes | (16) | (4) | (5) | (130) | – | (73) | (92) | – | – | – |
| Income tax expense | 0 | 0 | 0 | – | – | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (16) | (4) | (4) | (130) | (65) | – | (92) | – | – | – |
| Net income | (16) | (4) | (5) | (131) | – | (73) | (92) | (43) | (30) | (8) |
| Net income to common shareholders | (16) | (6) | (11) | (131) | – | (81) | (92) | – | – | – |